Now that long-acting injectables are formulated with second-generation antipsychotics — including aripiprazole, olanzapine, paliperidone, and risperidone — which have fewer adverse effects than first-generation antipsychotics, emerging evidence has led psychiatrists to consider these agents for patients with a first episode of schizophrenia.